Mark De Souza

Dr. Mark De Suuza is a Co-Founder and Board Member of MyoTherix, where he serves as Chief Operating Officer. He serves as Executive Chairman and President at Wings Therapeutics. He is also a Co-Founder and Board Member of NFlection Therapeutics. de Souza is a Co-Founder and Board Member of Chromaderm, where he serves as Chief Executive Officer and President. He is also an angel investor. He serves as Director at Excelimmune. He served as Chief Executive Officer and President at Lotus Tissue Repair, which he co-founded in 2010 to develop recombinant collagen VII as protein replacement therapy for a devastating orphan genetic disease, dystrophic epidermolysis bullosa. Lotus Tissue Repair secured a $26 million Series A commitment from Third Rock Ventures in 2011. The company was acquired by the Shire in early 2013. Prior to founding Lotus, he served as Vice President of Business Development at Dyax Corp, a biopharmaceutical company which discovered, developed and commercialized KALBITORe, its lead product in hereditary angioedema, an orphan genetic disease. Since 2003, he led the business development team, which was responsible for licensing Dyax's phage display technology and products, including KALBITOR, generating greater than $200 million in license fees and other forms of financing from a 50+ antibody, protein and peptide technology and product licensing transactions. Prior to joining Dyax, he conducted academic research at the University of California, Berkeley. From the University of California, Berkeley he earned a Ph.D.